The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...

President Joe Biden's outgoing administration on Thursday announced $211 million in new funding to develop mRNA vaccines ...

Dame Tracey Emin and Sir Grayson Perry are celebrated with solo exhibitions at the suitably palatial Palazzo Strozzi in ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

We recently published a list of 11 Stocks That Will Go to the Moon According to Reddit. In this article, we are going to take ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

The U.S. imposed caps on how many advanced AI chips can be exported to certain countries, overriding Nvidia's objections. Sha ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.